soluble frizzle receptor protein
Dipeptidylpeptidase inhibitor therapy increases circulating levels of anti- inflammatory soluble frizzle receptor protein (sFRP)-5 which in severe COVID-19 disease.
Dipeptidylpeptidase inhibitor therapy increases circulating levels of anti- inflammatory soluble frizzle receptor protein ( sFRP )-5 which in severe COVID-19 disease .